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Objective: The evaluation of central corneal thickness (CCT) in subjects with pesudoexfoliation 
glaucoma (PEXG), primary open-angle glaucoma (POAG), and in normotensive individuals 
with or without pseudoexfoliation syndrome (PXS).
Study design/patients and methods: CCT was evaluated with ultrasound pachymetry in 
a total of 179 individuals: 32 had bilateral PEXG, 55 had bilateral POAG, 35 had PXS, and 
57 were healthy individuals without PXS.
Results: CCT in PEXG eyes (526.00 ± 34.30 µm) was significantly thinner compared to POAG 
eyes (549.36 ± 39.3 µm) (P = 0.027) and normal control eyes with (550.64 ± 39.0 µm) or 
without PXS (547.36 ± 33.1 µm), (P = 0.039 and 0.048 respectively). No statistically significant 
difference was found comparing CCT values of POAG eyes to control group eyes.
Conclusion: The evaluation of CCT is necessary in all patients with glaucoma and especially 
in those with PEXG due to the thinner cornea and the risk of underestimation of intraocular 
pressure.
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Introduction
In routine clinical practice, intraocular pressure (IOP) is one of the most important 
parameters in the detection and monitoring of glaucoma. Goldmann applanation 
tonometry (GAT) has become the international “gold standard” for IOP measurements. 
The effect of central corneal thickness (CCT) on IOP readings using GAT has become 
a topic of much interest.1–7 A thick cornea would overestimate IOP and a thin one 
would underestimate it. Moreover the Ocular Hypertension Treatment Study (OHTS) 
designated CCT as a strong predictor for the development of primary open-angle 
glaucoma (POAG) in patients with ocular hypertension (OHT).8 Although the relation-
ship between CCT and stage of glaucoma damage seems to be related to IOP measuring 
error, recent studies recognize CCT as an intrinsic ocular factor in the pathogenesis 
and progression of glaucoma.9–11
Being aware of these evidence, CCT assessment has been extensively studied in 
patients with POAG and has been shown to be thinner12–14 or similar4,15–19 to control 
individuals.
Pseudoexfoliation glaucoma (PEXG) is generally accepted as being more 
unpredictable and resistant to the treatment (surgical or medical) compared to POAG. 
Furthermore, the conversion of hypertensives with pseudoexfoliation syndrome (PXS) to 
glaucoma has been found to be more common than conversion of ocular hypertensives Clinical Ophthalmology 2009:3 538
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without PXS.20 In that way, evaluation of CCT in subjects 
with PXS or PEXG could be essential for early diagnosis 
and suitable management of the glaucoma. However, there 
are very few studies conducted in a small number of patients 
in the literature measuring the CCT in this type of glaucoma 
and their results are controversial.4,6,12,13,15,16,21,22
The aim of this study is the evaluation of central CCT in 
patients with PEXG, POAG, and in normotensive individuals 
with or without PXS.
Patients and methods
A total of 179 subjects (179 eyes), all Caucasians, were 
included in this cross-sectional study by a single observer. 
All subjects where examined in University Eye Clinic of 
Ioannina, within the context of routine examinations at the 
Glaucoma department between September 2007 and March 
2008. Thirty-two subjects (32 eyes) had bilateral PEXG 
and 55 subjects (55 eyes) had bilateral POAG. The type of 
glaucoma had been diagnosed in previous appointments. 
Ninety two individuals (92 eyes) without glaucoma or OHT 
were also included in the study, comprising the control 
group. Thirty-five subjects (35 eyes) had bilateral PXS and 
57 individuals (57 eyes) were normal without PXS.
All eyes underwent a full ophthalmologic examination, 
including applanation tonometry, gonioscopy, fundoscopy, 
and repeated Humphrey 24–2 static threshold perimetry 
(at least three examinations).
Data such as age, gender, ocular and medical history, 
number, type, and duration of antiglaucomatous medical 
therapy were also recorded.
Inclusion criteria for subjects with POAG were: untreated 
IOP more than 22 mmHg on at least two diurnal curves, 
open-normal angle, glaucomatous optic disc and at least 
three Humphrey visual field tests with glaucomatous defects. 
Inclusion criteria for subjects with PEXG were: untreated IOP 
more than 22 mmHg, open angle, glaucomatous optic disc, 
at least three Humphrey visual field tests with glaucomatous 
defects and presence of typical pseudoexfoliative material 
at the anterior lens capsule and/or at the pupillary margin. 
On the day of examination, IOP measured by GAT was less 
than 21 mmHg in all individuals with glaucoma.
Control group included subjects with IOP less than 
21 mmHg, at three different successive measurements, open 
angle, normal optic disc, and Humphrey visual field tests and 
no family history of glaucoma. The control group was also 
evaluated for the presence of pseudoexfoliation syndrome 
(presence of typical pseudoexfoliative material at the anterior 
lens capsule and/or at the pupillary margin).
Subjects with ocular disease other than glaucoma, contact 
lens users and patients that had undergone ocular surgery 
or laser photocoagulation treatment were excluded. Also, 
subjects with myopia or hypermetropia greater then 3D or 
astigmatism more than 1D that could potentially effect our 
measurements were not included.
In all understudy groups, IOP was measured using 
calibrated GAT. Two measurements were made. If the two 
readings were within 2 mmHg, the mean of the two measure-
ments was used. If the two readings were separated by more 
than 2 mmHg, a third measurement was made and the median 
became the recorded IOP.
The estimation of optic disc cupping (vertical C/D ratio) 
and retinal nerve fiber layer (RNFL)-average thickness (Avg. 
Thick.) was made with optical coherence tomography (Zeiss 
Stratus; Carl Zeiss, Inc., Valhalla, NY, USA).
Ultrasound pachymetry (Pacline; OPTIKON 2000 S.p.A, 
Rome, Italy) was used to obtain morning measurements, at 
least two hours after awakening, of central corneal thickness 
by a single observer. Repeated sets of five readings at the 
center of the cornea were taken, after a drop of anesthetic, 
until the standard deviation for the five readings were 5 µm 
or less. Pachymetry always precedes applanation tonometry. 
One eye was randomly selected from each patient and ana-
lyzed in the study.
The measurements in each glaucoma type subgroup were 
compared against the age and sex matched control group.
Statistical analysis was performed with SPSS (v.15 for 
Windows XP; SPSS Inc., Chicago, IL, USA). One-way analy-
sis of variance, Student’s t-test and Chi squared (χ2) test were 
used. One-way analysis of variance (ANOVA) using the Tukey 
post-hoc test was used to identify which groups (PXEG, POAG, 
control with or without PXS) differed from each other. We 
considered values of P  0.05 to be statistically significant.
Results
Eighty-seven subjects with glaucoma (32 with PEXG, 
55 with POAG) and 92 control subjects (35 with PXS, 
57 without PXS) met the inclusion criteria of the study. The 
demographic characteristics of each group are summarized 
in Table 1. All groups are similar in age and gender. Mean 
IOP measurements of subjects with glaucoma (POAG, 
PEXG) and of control group were below 21 mmHg, thus 
avoiding false measurements due to corneal edema (Table 1). 
PEXG individuals had statistically significant more severe 
glaucomatous optic nerve damage, as this is revealed by C/D 
ratio and RNFL thickness, compared to subjects with POAG 
(Table 1; Student’s t-test, P = 0.03 and 0.01, respectively).Clinical Ophthalmology 2009:3 539
Central corneal thickness Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
As far as the glaucoma subgroups are concerned, the study 
showed that they did not vary in type of topical antiglaucoma 
medication treatment. Topical carbonic anhydrase inhibi-
tors and prostaglandine analogues were given to a similar 
percentage of patients in the two glaucoma subgroups. Also, 
the duration of topical antiglaucoma treatment was similar 
in both glaucoma subgroups.
Regarding CCT, our results showed the following mean 
measurements in the groups under study: 526.00 ± 34.30 µm 
in eyes with PEXG, 549.36 ± 39.3 µm in eyes with POAG, 
550.64 ± 39.0 µm in the control group with PXS, and 
547.36 ± 33.1 in the control group without PXS (Table 2, 
Figure 1). No statistically significant difference was found 
when comparing CCT values of subjects with POAG to 
control group with or without PXS (one-way ANOVA test, 
P = 0.999 and 0.991, respectively). However, subjects with 
PEXG had statistically significant thinner cornea compared 
to all the other groups (one-way ANOVA test: POAG group, 
P = 0.027; control group with PXS, P = 0.039; and control 
without PXS, P = 0.048). Finally CCT was similar between 
control groups with or without pseudoexfoliation (one-way 
ANOVA test, P = 0.992).
Discussion
It is well known that CCT affects IOP measurements using 
Goldmann applanation tonometry.1–7 Furthermore, OHTS8 
demonstrated that CCT is also an important and independent 
risk factor for progression to initial glaucoma damage among 
persons with ocular hypertension. This could be attributed 
either to the fact that thinner corneas give lower measured 
IOP levels and these eyes may be subjected to less aggressive 
IOP-lowering therapy, or thinner corneas may be a risk factor 
due to an association with the response of the corneoscleral 
shell and ocular vasculature to IOP-induced stress.
In our study, CCT in POAG eyes did not have any 
significant difference compared to normal eyes. Our results 
are in concordance with many published studies.4,15–19,22 
Ventura and colleagues,16 Herndon and colleagues,6 and 
Copt and colleagues19 compared CCT in patients suffering 
from POAG and in normal people and concluded that CCT 
does not differ significantly in these two groups. Although 
the small sample sizes of these studies could be an issue, 
Shah and colleagues,4 Jonas and colleagues,18 and Lee and 
colleagues17 came to the same conclusion when the CCT 
of 335, 215, and 343 eyes with POAG, respectively, were 
compared to normal eyes. On the contrary, according to 
other reports, CCT in POAG patients was found to be thin-
ner compared to normal individuals.12–14 This difference 
could be attributed to the different ethnical make-up of the 
study populations.12 Investigators have shown that CCT 
is thinner in African Americans compared to Asians and 
Caucasians.23–25 Furthermore, more African Americans are 
likely to be in the POAG group since the incidence of POAG 
is higher in this race. However these demographic data are 
Table 1 Characteristics for each of the investigated groups
PEXG POAG P CTL-PXS CTL P
Age (years) 71.2 ± 6.7 69.5 ± 8.5 0.05 71.4 ± 8.2 69.4 ± 11.1 0.05
sex *Male  
    Female
15  
17
27  
28
0.05 17  
18
28  
29
0.05
iOP (mm hg) 15.7 ± 6.3 15.2 ± 2.5 0.05 13.9 ± 3.14 14.2 ± 2.3 0.05
C/D ratio† 0.60 ± 0.22 0.45 ± 0.19 0.03 0.28 ± 0.1 0.25 ± 0.075 0.05
Avg RnFL thickness 
(µm)††
66.1 ± 15.2 75.8 ± 13.6 0.01 99.4 ± 10.2 100.1 ± 10.2 0.05
Duration of medication 
(months)
36.2 ± 6.2 36.4 ± 6.3 0.05 – – –
number of medications 1.43 ± 0.07 1.54 ± 0.08 0.05 – – –
(Prost.or/and CAis)*
  Prost  
  CAis  
  Prost and CAis
22/32 (78.2%)  
16/22  
3/22  
3/22
43/55 (68.8%)  
31/43  
6/43  
6/43
0.05  
0.05  
0.05  
0.05
– – –
n 32 55 35 57
Notes: †Comparison of PEXG to POAG; statistically significant at P = 0.03 (0.05) student’s t-test; ††Comparison of PeXg to POAg: P = 0.01 (0.05) student’s t-test; 
*Chi squared test.
Abbreviations: POAg, primary open-angle glaucoma; PeXg, pseudoexfoliation glaucoma; CTL-PXs, Control group with pseudoexfoliation syndrome; CTL, control group 
without pseudoexfoliation syndrome; C/D ratio, cup to disc ratio; Prost, prostaglandin analogues; CAis: carbonic anhydrase inhibitors.Clinical Ophthalmology 2009:3 540
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not presented in most of the above reports. Alternatively, it 
has been shown26 that CCT is a powerful clinical factor in 
determining glaucoma severity at the initial examination by 
a glaucoma specialist. POAG patients with lower CCT had 
worse baseline visual fields than patients presenting thicker 
CCT.18,27–29 In the light of this evidence, differences of the 
glaucoma stage between POAG groups among the various 
studies could be at least partially responsible for the disparate 
conclusions.
Concerning CCT in subjects with PEXG and PXS, 
references in the literature are limited and to a certain degree 
ambiguous. Previous studies have shown that CCT in patients 
with PEXG is thinner compared to the control individuals.12,13,15 
More specifically, studies by Aghaian and colleagues12 using 
an ultrasonic pachymeter have shown that the CCT in patients 
with PEXG is statistically significant thinner compared to 
normal individuals. Bechmann and colleagues13 reached the 
same conclusion with optical coherence tomography. However, 
according to other investigators, although CCT was lower in 
PEXG compared to control subjects this difference was not 
statistically significant.4,6,16,21,22 The basis for these discordant 
results is unclear. The small number of included subjects could 
be a limitation at these studies and could also account for the 
controversial results.
In their study, Hepsen and colleagues30 reported that the 
mean CCT (546.4 µm) in eyes with PXS was not significantly 
different compared to control eyes (542.9 µm) using optical 
pachymetry. When those eyes were subcategorized, according 
to IOP, the CCT was significantly thinner in normotensive 
PXS eyes compared to those with hypertensive PXS and 
PEXG eyes. However, hypertensive PXS and PEXG eyes 
had an IOP higher than 21 mmHg and this could affect the 
CCT measurements, considering also the fact that corneal 
endothelial density is decreased in PXS eyes.21
We included a higher number of PEXG subjects in our 
study compared to the reports above. We further subcatego-
rized the control individuals depending on the presence or not 
of PXS. Our results showed that PEXG eyes had thinner CCT 
compared to POAG and normal eyes (with or without PXS).
Kniestedt and colleagues25 compared PEXG to POAG 
patients and came to the same conclusion although the 
POAG group in that study was multiracial. Other reports 
did not show a difference in CCT between PEXG and POAG 
subjects, but either the number of PEXG eyes was small4,16,22 
or the POAG group was multiracial.12 Differences in the usage 
of carbonic anhydrase inhibitors and prostaglandin analogues 
as antiglaucoma medications has been shown to affect CCT 
readings,6,31–33 but could not explain our result since there was 
no variation between the two glaucoma groups concerning 
their treatment.
A question that arises from our findings is why eyes 
with PEXG present a thinner cornea compared to those with 
POAG and PXS.
In our study, subjects with PEXG were recruited from 
the hospital where they presented with more advanced, 
glaucoma alterations and thinner CCT compared to subjects 
with POAG. This fact could be attributed to a delay in the 
diagnosis or to deficient treatment of subjects with PEXG 
by their ophthalmologists prior to their visit to our glaucoma 
department. Indeed, the systematic underestimation of IOP 
in people with undiagnosed PEXG and thinner corneas, 
taking into account the nature of PEXG and PXS as having 
major variations in IOP, deprived the ophthalmologist 
of the diagnostic value of the most important risk factor 
(IOP) for the development of glaucoma as well as of the 
possibility of achieving “target pressure”. Because of this, 
subjects developed more advanced glaucomatous alterations 
which led them to a more specialized glaucoma unit in our 
geographical area in order to be re-evaluated (glaucoma 
department, University Hospital). This is further confirmed 
by previous studies, where a significant negative correlation 
was found between CCT and C/D ratio,25,26 which indicates 
that patients with thin corneas are more likely to be found 
in an advance stage of glaucoma at their first presentation. 
In this way, subjects with advanced PEXG and thin CCT 
probably enriched our sample and their comparison with 
less advanced POAG subjects and PXS individuals gave us 
this statistical result.
If we take for granted that the CCT is an independent 
biological risk factor, then the co-existence of PXS and thin 
cornea may increase the risk for development of PEXG. 
There are studies that indicate a possible biological link 
between aspects of the front of the eye that can be measured, 
such as thickness or material properties of the cornea, and 
the structure, deformability, or physiology of the optic disc, 
lamina cibrosa, and peripapillary sclera. Findings by OHTS8 
and other studies9–11 have generated an enormous interest 
Table 2 Central corneal thickness in glaucoma subgroups and 
control group
PEXG POAG CTL-PXS CTL
CCT 
(µm)
526.00 ± 34.30† 549.36 ± 39.3 550.64 ± 39.0 547.36 ± 33.1
Note: †Statistically significant at P = 0.021 (0.05) AnOVA test.
Abbreviations: CCT, central corneal thickness; POAg, primary open-angle glaucoma; 
PeXg, pseudoexfoliation glaucoma; CTL-PXs, control group with pseudoexfoliation 
syndrome; CTL, control group without pseudoexfoliation syndrome.Clinical Ophthalmology 2009:3 541
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in the material properties of the ocular coats of the eye and 
the likelihood that they may be an underlying factor in some 
aspects of the genetic susceptibility to glaucoma. Leske and 
colleagues9 used confocal scanning laser opthalmoscopy to 
measure the movement of lamina cibrosa after profound IOP 
lowering. They found that the lamina moved forward more in 
patients with thin corneas than in those with thick corneas. 
Pakravan and colleagues10 reported that CCT was linked to 
disc size and thicker corneas were associated with smaller 
optic disc. Finally, Toh and colleagues11 showed that CCT is 
among the most heritable aspects of ocular structure. There 
may be a biological link between the anterior chamber of 
the eye (such as CCT) and the peripapillary scleral tissue 
as well as the properties of the lamina cibrosa. If such a 
biological link is real then the co-existence of thin CCT 
with another predisposing factor for the development of 
glaucoma such as PXS increases the risk of glaucoma in 
those individuals.
Finally, we showed that CCT was not affected by the 
presence of pseudoexfoliation in individuals without glaucoma 
and our result is in agreement with previous studies.34,35 On the 
contrary, Inoue and colleagues21 reported thinner corneas 
in individuals with PXS compared to the control. Finally, 
Puska and colleagues36 reported that CCT in eyes with PXS 
was thicker than the CCT found on the other eye of the same 
patient that did not have PXS.
In conclusion, our report demonstrates that CCT in 
subjects with PEXG was statistically significant thinner 
compared to the CCT of the rest understudy group and 
specially compared to CCT of individuals with PXS. This 
may be a statistic result but it could also indicate a possible 
independent biological role of CCT as a risk factor for the 
development of glaucoma in subjects with PXS. In that 
way CCT must be assessed in patients with PXS in order to 
avoid the underestimation of IOP (in cases with thin cornea). 
In addition, CCT must be determined in all glaucoma patients 
in order to achieve “target pressure”, especially in patients 
with PEXG due to the nature of the disease (major variations 
of IOP).
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Figure 1 Central corneal thickness (CCT) in glaucoma subgroups and control group. The CCT values were measured with the PACLine OPTiCOn 2000 s.p.A. The mean 
CCT with error bars in the different glaucoma and control groups are plotted.
Note: *statistically significant at P = 0.021 (0.05) AnOVA test.
Abbreviations: POAg, primary open-angle glaucoma; PeXg, pseudoexfoliation glaucoma; CTL-PXs, control group with pseudoexfoliation syndrome; CTL, control group 
without pseudoexfoliation syndrome; CI, confidence interval.Clinical Ophthalmology 2009:3
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